Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Chimeric Therapeutics - Appendix 2A (ASX:CHM)

To view the Application for quotation of +securities, download the attached PDF.

Chimeric Therapeutics - Half Yearly Report and Accounts (ASX:CHM)

To view the report, download the attached PDF.

CARETEQ - Half Year Results Presentation (ASX:CTQ)

To view the presentation, download the attached PDF.

CARETEQ - Appendix 4D & Half Year Results (ASX:CTQ)

Highlights: -- Interim revenue jumps >6 times to $1.9m due to Ward MM acquisition and sharp increase in active SaaS platform users -- Number of users grows 579% pcp to >3k and Ward MM prof...read more

Carbonxt Group - HY22 Results Announcement (ASX:CG1)

-- Revenue of $9.9 million, up 38% on HY21 reflecting several factors including increased economic activity at the tail end of the pandemic, higher natural gas pricing, a warmer summer and successfu...read more

Carbonxt Group - Half Yearly Report and Accounts (ASX:CG1)

To view the report, download the attached PDF.

Chimeric Therapeutics - Successful completion of Institutional Entitlement Offer (ASX:CHM)

Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) refers to its announcement of 21 February 2022 in relation to an equity raising being undertaken by the Company by way of an accelerated...read more

Chimeric Therapeutics - Prospectus (ASX:CHM)

Accelerated non-renounceable pro rata entitlement offer of 1 New Share for every 3.15 Existing Shares (and one New Option for every New Share issued) at an offer price of $0.17 per New Share to rais...read more

Chimeric Therapeutics - Appendix 3B (ASX:CHM)

To view the appendix, download the attached PDF.

Chimeric Therapeutics - Entitlement Offer to raise approximately $18.1 million (ASX:CHM)

Key Points -- Accelerated non-renounceable entitlement offer to raise approximately $18.1 million (before costs) -- Offer price of $0.17 per new share, a 15% discount to the closing price of Chi...read more

Chimeric Therapeutics - Trading Halt (ASX:CHM)

The securities of Chimeric Therapeutics Limited (‘CHM’) will be placed in trading halt at the request of CHM, pending it releasing an announcement regarding the outcome of the institutio...read more

Carbonxt Group - Successful $4.5m Placement (ASX:CG1)

Carbonxt Group Limited (Carbonxt or the Company) is pleased to announce that it has successfully raised $4.5m (before costs) through the placement (“the Placement”) of 18.7m new fully pa...read more

Carbonxt Group - Trading Halt (ASX:CG1)

The securities of Carbonxt Group Limited (‘CG1’) will be placed in trading halt at the request of CG1, pending it releasing an announcement. Unless ASX decides otherwise, the securities ...read more

Chimeric Therapeutics - Encouraging data from 2nd dose cohort in CLTX CAR T trial (ASX:CHM)

-- Encouraging safety for dual routes (intratumoral and intraventricular) of CLTX chimeric antigen receptor (CAR) T cell administration as therapy was generally well tolerated -- Initial signal for...read more

Chimeric Therapeutics - Sponsored Research Agreement with University of Pennsylvania (ASX:CHM)

-- Chimeric has executed a three-year Sponsored Research Agreement with the University of Pennsylvania, for research to be conducted in the laboratory of Xianxin Hua, MD, PhD -- The research will f...read more

Viewing: 151 - 165 of 200 Previous | Next